Pharming Group N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
25 mei 2010 - 07:59
Statutaire naam
Pharming Group N.V.
Titel
PHARMING SUBMITS D180 RESPONSE FOR RHUCIN MAA TO EMA WITHOUT CLOCK STOP - Final opinion now expected by end of June
Bericht
Leiden, The Netherlands, May 25, 2010. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) announces that it has submitted its response to the Day 180 List of Outstanding Issues (LoOI) to the Committee for Medicinal Products for Human Use (CHMP) in regard to its European Marketing Authorization Application (MAA) for Rhucin without an additional clock stop. The expected date for a CHMP opinion has been advanced with another month and is now expected end of June 2010.
Gerelateerde downloads
Datum laatste update: 28 december 2025